Novel treatment approaches are needed for children with advanced neuroblastoma. Studies with neuroblastoma cells have indicated the presence of a hypoxiadriven vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-1 autocrine loop modulating hypoxiainducible factor-1alpha (HIF-1a). Whether other receptor tyrosine kinases (RTKs) are capable of modulating HIF1a levels and whether RTKs can regulate HIF-2a as well is largely unknown. We evaluated neuroblastoma cell lines for expression of various RTKs. Although cell lines were heterogeneous in the expression of VEGFR-1, -3, c-Kit and RET, most cells expressed PDGFR-a and -b. Ligandinduced activation of multiple RTKs upregulated HIF-1a levels, whereas activation of VEGFR-1 alone upregulated HIF-2a. Multitargeted tyrosine kinase inhibitor sunitinib reduced hypoxia-induced rises in HIF-1a and HIF-2a through mechanisms involving effects on both mRNA levels and protein stability. In addition, sunitinib and sorafenib had direct effects on tumor cell viability in vitro. In a neuroblastoma xenograft model, tumor growth inhibition by sunitinib was associated with inhibition of angiogenesis and reduced HIF-1a levels. These findings show that multiple RTKs may regulate the HIF axis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects not only by direct effects on endothelial cells, but also by blocking compensatory hypoxia-and ligand-induced changes in HIF-1a and HIF-2a.
Introduction
Neuroblastoma is the most common extracranial solid tumor in children (Ladenstein et al., 1998) . Nearly half of newly diagnosed patients are considered 'high-risk' as assessed according to current Children's Oncology Group guidelines. Children with high-risk neuroblastoma have very poor outcomes, with 5-year disease-free survival rates between 25 and 35% (Ladenstein et al., 1998; Matthay et al., 1999; Kaneko et al., 2002) . Highrisk neuroblastoma is associated with frequent relapses and chemotherapy resistance (Kushner et al., 2000; Donfrancesco et al., 2004; Maris et al., 2007) . Novel therapies are needed for children with high-risk and recurrent neuroblastoma.
The growth of solid tumors is dependant on an adequate vasculature, and angiogenesis has been validated as a therapeutic target for at least some malignancies. High levels of angiogenesis or proangiogenic regulators have been associated with a poor clinical outcome in neuroblastoma (Meitar et al., 1996; Eggert et al., 2000; Komuro et al., 2001; Peddinti et al., 2007) . However, this is controversial, and conflicting findings have been reported (Canete et al., 2000) . A key regulator of numerous genes critical for tumor angiogenesis, such as vascular endothelial growth factor (VEGF), is hypoxia-inducible factor (HIF). In hypoxia the a-subunits (HIF-1a and HIF-2a) are stabalized and subsequently bind to the constitutively expressed HIF-1b, thus initiating transcription of target genes (Hanahan and Folkman, 1996; Semenza, 2003) . In neuroblastoma cells, HIF-2a levels are elevated at higher oxygen tensions (5% O 2 ) and in response to chronic hypoxia (Holmquist-Mengelbier et al., 2006) . In clinical specimens, HIF-2a levels correlate with VEGF expression and poor outcome (Holmquist-Mengelbier et al., 2006) . HIF-2a expression in cancer cells promotes the expression of markers of epithelial-mesenchymal transition (Kim et al., 2009) .
Activation of receptor tyrosine kinases (RTKs) may stimulate rises in HIF-1a in a cell type-specific manner. In particular, epidermal growth factor receptor (EGFR) modulates HIF-1a levels in prostate, lung and breast cancer cells (Zhong et al., 2000; Phillips et al., 2005; Peng et al., 2006) . Studies in neuroblastoma cells have indicated the presence of a hypoxia-driven VEGF/ VEGFR-1 autocrine loop modulating HIF-1a (Das et al., 2005) . Whether other RTKs are capable of modulating HIF-1a, and whether RTKs can modulate HIF-2a levels is unknown.
Previous reports suggest that targeting the vascular component of neuroblastoma may be an effective therapeutic strategy (Katzenstein et al., 2001; Shusterman and Maris, 2005; Beaudry et al., 2008; Maris et al., 2008) . Small-molecule tyrosine kinase inhibitors (TKIs) such as sunitinib (which inhibits VEGF receptor (VEGFR)-1, -2 and -3, platelet-derived growth factor receptor (PDGFR), c-Kit and RET) and sorafenib (which inhibits VEGFR-2 and -3, PDGFR, BRAF, RET and c-Kit) have been shown to restrict tumor angiogenesis in multiple tumor types (O'Farrell et al., 2003; Wilhelm et al., 2004) . Although sunitinib and sorafenib were designed to primarily target the tumor vasculature, there is evidence that neuroblastoma cells themselves may express VEGFR-1, PDGFR and RET. Neuroblastoma tumors have been shown to express PDGFR and c-Kit (Beppu et al., 2004) , and VEGFR-1 is elevated in advanced-stage neuroblastoma (Cohen et al., 1994; Meister et al., 1999; Langer et al., 2000; Fakhari et al., 2002) . We and others have shown RET overexpression on neuroblastoma cells (Nakamura et al., 1994; Hishiki et al., 1998; Beaudry et al., 2008) , and activation of RET by its ligand, glial-derived neurotrophic factor (GDNF), initiates cell proliferation, migration and survival (Richardson et al., 2006) . Whether sunitinib or sorafenib has direct activity against neuroblastoma cells is unknown. Therapeutic modalities with dual activity against tumor cells and the tumor vasculature will likely show greater efficacy than drugs targeting either component alone, therefore, addressing these questions is of great clinical significance.
In this study, we evaluated neuroblastoma cell lines and observed heterogenous expression of multiple RTKs, including RET, PDGFR-a and-b, c-Kit, and VEGFR-1,-2 and -3. Ligand-induced activation of RET, VEGFR-1, PDGFR-b and EGFR resulted in increased HIF-1a expression. We observed differential regulation of HIF-1a and HIF-2a by RTK activation. Multikinase inhibition abrogated hypoxia-induced rises in HIF and exerted direct effects on tumor cell viability, whereas knockdown of any single RTK had only a minimal effect. Collectively, these data suggest that RTKs may regulate critical pathways in a redundant manner in neuroblastoma cells, and that multikinase inhibitors may exert their antiangiogenic activity through effects on both tumor cells and tumor-associated vasculature.
Results

Neuroblastoma cell lines express multiple RTKs
We evaluated seven neuroblastoma cell lines (SK-N-SH, SH-SY5Y, CHP-134, LA1-55N, NGP, SH-EP and SK-N-AS) for expression of various RTKs (RET, PDGFR-a, PDGFR-b, VEGFR-1, -2 and -3, and c-Kit). Each cell line expressed at least one of the RTKs; all the levels and number of RTKs varied. SK-N-SH, SH-SY5Y, NGP and SK-N-AS cells expressed detectible levels of RET, and the majority of cell lines expressed PDGFR-a and -b as determined by immunoblotting ( Figure 1a) . Lysates from an osteosarcoma cell line (MG-63) served as a positive control for PDGFR. We evaluated the expression of VEGFR-1, -2 and -3 and c-Kit by flow cytometry and observed that VEGFR-2 expression was minimal for all cell lines (Figure 1b ). VEGFR-3, which is typically restricted to lymphatic endothelium and some high endothelial venules (Kaipainen et al., 1995) but recently reported to be expressed on some malignant cells (Witte et al., 2002; Kaushal et al., 2005) , was observed on LA1-55N and SK-N-AS cells. VEGFR-1 was detected at high levels on SK-N-AS cells.
RTK activation increases HIF-1a levels
Others have demonstrated that activation of EGFR increase HIF-1a levels in a cell type-specific manner (Zhong et al., 2000; Phillips et al., 2005) . VEGFR-1 activation was shown to modulate HIF-1a levels in neuroblastoma cells (Das et al., 2005) . To determine whether ligand-induced activation of other RTKs, such as RET, PDGFR-b or EGFR, modulates HIF-1a in neuroblastoma cells, we cultured SK-N-AS cells without serum overnight and then stimulated them with 50 ng/ml GDNF, VEGF-B, EGF and PDGF-BB for 3 and 15 h. Protein lysates were isolated and HIF-1a levels were evaluated by western blotting (Figure 2a) . Ligand-induced activation of VEGFR-1 and PDGFR-b resulted in robust increases in HIF-1a expression at 3 and 15 h. Activation of RET and EGFR with GDNF and EGF, respectively, resulted in modest yet detectable rises in HIF-1a. Prolonged exposure (48 h) to PDGF-BB (P ¼ 0.006) and GDNF (P ¼ 0.006) resulted in sustained HIF-1a elevation as determined by enzyme-linked immumosorbent assay (ELISA) (Figure 2b ).
Sunitinib and sorafenib inhibit hypoxia-induced expression of HIF-1a
On the basis of our finding that RET, VEGFR-1 and PDGFR-b activation augmented HIF-1a levels, we investigated whether pharmacological inhibition of RTK activity could abrogate hypoxia-induced HIF-1a expression. SK-N-AS cells were incubated in normoxia or hypoxia (0.1% O 2 ) with or without 1 mM sunitinib, sorafenib or imatinib, a TKI with activity against PDGFR and c-Kit. HIF-1a levels were evaluated by western blotting. In hypoxia, HIF-1a expression was elevated compared with normoxic levels. Treatment with sunitinib and sorafenib, but not imatinib, diminished hypoxia-induced HIF-1a expression (Figure 2c ). Separately, SK-N-AS cells were incubated in normoxia or hypoxia with or without 1 mM sunitinib, sorafenib or imatinib for 8 h and HIF-1a levels were evaluated by ELISA (Figure 2d ). HIF-1a increased in response to hypoxia (P ¼ 0.001), and sunitinib (P ¼ 0.007) and sorafenib (P ¼ 0.04) significantly inhibited hypoxiainduced HIF-1a. Similarly, sunitinib reduced hypoxiainduced HIF-1a levels in SH-SY5Y cells (Supplementary Figure 1) . We observed that in normoxia HIF-1a is detectable at low levels in neuroblastoma cell lines. Given our observation that RTKs modulate HIF-1a, this is likely due to autocrine RTK signaling. To validate our HIF1a detection methods, we transfected SK-N-AS cells with small interfering RNA (siRNA) against HIF-1a and HIF-2a and evaluated HIF-1a levels by ELISA. HIF-1a levels increase in hypoxia compared with normoxia (P ¼ 0.02; Figure 2e ). HIF-1a targeting siRNA decreases HIF-1a levels to below normoxia values (Po0.0001 versus hypoxia control).
Sunitinib and sorafenib decreased hypoxia-induced HIF-1a mRNA levels SK-N-AS cells were pretreated with or without 1 mM sunitinib, sorafenib or imatinib (in 0% fetal bovine serum (FBS) media) for 1 h and then incubated in normoxia or 0.1% O 2 for 3 h. RNA was collected and HIF-1a mRNA relative to GAPDH RNA was evaluated by reverse transcriptase PCR. Sunitinib (P ¼ 0.006), sorafenib (P ¼ 0.003), and, to a lesser extent, imatinib (P ¼ 0.03) significantly inhibited hypoxia-induced rises in HIF-1a RNA ( Figure 2f ).
RTK activation modulates HIF2-a levels
We investigated whether RTK activity can modulate HIF-2a levels. In contrast to HIF-1a, which was modulated by multiple RTKs tested, rises in HIF-2a were only observed with VEGF-B stimulation ( Figure 3a ). HIF-2a levels returned to baseline levels by 48 h. Treatment of SK-N-AS cells with 1 mM sunitinib or imatinib, but not sorafenib, diminished HIF-2a expression in hypoxia ( Figure 3b ). TKI-mediated decrease in HIF-2a occurred in a proteosome-dependent manner, as treatment with 10 mM of the proteosome inhibitor MG-132 abrogated the effect of sunitinib and imatinib. In addition, SK-N-AS cells were incubated in 0.1% O 2 with media containing 100 ng/ml cyclohexamide with or without 1 mM sunitinib. In the presence of cyclohexamide alone, HIF-2a remained stable for up to 100 min ( Figure 3c ). With the addition of sunitinib decreases in HIF-2a were detected as early as 30 min.
To evaluate whether TKIs could decrease HIF-2a mRNA levels, SK-N-AS cells were pretreated with 1 mM drug and incubated in 0.1% O 2 for 6 h. Reverse transcriptase-PCR revealed that hypoxia induced a significant increase in HIF-2a mRNA (P ¼ 0.04), and this rise in HIF-2a mRNA was blocked with the addition of sunitinib (P ¼ 0.03) or imatinib (P ¼ 0.04) but not sorafenib (Figure 3d ).
Sunitinib and sorafenib decrease VEGF secretion in neuroblastoma cells SK-N-AS, SH-SY5Y and NGP cells were incubated with 1 mM sunitinib or sorafenib in normoxia or hypoxia. ELISA showed that in nearly all cell lines tested, sunitinib and sorafenib caused a modest yet significant decrease in VEGF production in both normoxia and hypoxia ( Figure 3e ).
Sunitinib and sorafenib have direct activity against neuroblastoma cells in vitro Given the finding that neuroblastoma cells expressed multiple RTKs inhibited by sunitinib, sorafenib and imatinib, we evaluated the effect of these drugs on tumor cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol-tetrazolium bromide (MTT) assay. For all but two cell lines, sunitinib inhibited cell viability by 50% (IC 50 ) at or below 1 mM (Figure 4a ). Although sorafenib also decreased the viability of neuroblastoma cells, the cells were less sensitive to sorafenib than to sunitinib, with an IC 50 at or above 5 mM (Figure 4b ). Because neuroblastoma cells expressed PDGFR-a and -b, we evaluated whether inhibition of PDGFR or c-Kit was primarily responsible for the direct antitumor effects of sunitinib and sorafenib. We treated neuroblastoma cells with imatinib, which targets PDGFR and c-Kit. Imatinib had a minimal antitumor effect, with an IC 50 above 10 mM observed for all cell lines tested except for SH-SY5Y and SK-N-SH cells (Figure 4c ).
Effect of sunitinib and sorafenib on apoptosis and proliferation of neuroblastoma cells
We treated SH-EP, SK-N-AS and CHP-134 cells with 1 mM sunitinib or sorafenib for 72 h and evaluated DNA content by propidium iodide staining and flow cytometry ( Figure 5 ). Sunitinib increased tumor cell apoptosis and decreased the number of cycling cells. Similarly, sorafenib reduced the percentage of cycling cells in all cell lines tested and increased cell death in SH-EP and CHP-134 cells. Consistent with data generated by MTT assay, sunitinib exerted its effects at lower concentrations than sorafenib.
Inhibition of individual RTKs is insufficient to kill neuroblastoma cells
We transfected SK-N-AS cells with control siRNA or siRNA directed against RET, PDGFR-b or VEGFR-1. Western blotting showed knockdown of targeted RTKs (Figures 6a-c) . To determine whether knockdown of RET, VEGFR-1 or PDGFR-b individually was adequate to abrogate hypoxia-induced HIF-1a, SK-N-AS cells transfected with siRNA and after 72 h were cultured in normoxia or 0.1% O 2 for 8 h. HIF-1a levels were evaluated by ELISA. Knockdown of individual RTKs did not diminish hypoxia-induced HIF-1a (Figure 6d) . Knockdown of RET, VEGFR-1 or PDGFR-b resulted in slight but statistically significant changes in the growth rate of neuroblastoma cells as determined by MTT assay. Therefore, inhibition of these individual RTKs is insufficient to cause major effects on neuroblastoma cell viability. We did not observe any change in cell growth rate with control siRNA or siRNA targeting HIF-1a or HIF-2a (Figure 6e ).
Sunitinib inhibits migration of neuroblastoma cells
Hypoxia has been shown to promote tumor cell invasiveness through HIF (Pennacchietti et al., 2003; Semenza, 2003) . In agreement with previous findings (Das et al., 2005) , our data showed that VEGFR-1 activation increased HIF-1a in neuroblastoma cells. Because VEGFR-1 has been shown to facilitate monocyte motility, we investigated the chemotactic effect of VEGFR-1 activation on neuroblastoma cells and evaluated whether sunitinib or sorafenib could inhibit neuroblastoma cell motility. We treated SK-N-AS cells with VEGF-B with or without sunitinib or sorafenib and measured tumor cell migration by Boyden chamber assay (Figure 7a ). VEGF-B stimulation resulted in an increase in the numbers of migrating cells (P ¼ 0.03). Sunitinib (P ¼ 0.001), but not sorafenib, decreased tumor cell migration to levels below baseline values, suggesting that VEGFR-1 contributes to neuroblastoma cell migration.
Sunitinib inhibits growth of neuroblastoma tumors in vivo SK-N-SH cells were injected into NOD/SCID mice; once tumors were palpable (B5 mm in diameter), animals began treatment with either daily vehicle (1% Tween-20) or 40 mg/kg sunitinib by oral gavage. Sunitinib effectively inhibited tumor growth (Figure 7b ). Control tumors appeared more highly vascularized than sunitinib-treated tumors (Figure 7c) . Separately, animals bearing SK-N-SH tumors were treated with vehicle or sunitinib for 5 days, and tumors were collected for molecular studies. We evaluated HIF-1a levels in tumors by ELISA and observed a significant decrease in HIF-1a in sunitinib-treated tumors versus controls (Figure 7d ; P ¼ 0.02). Immunohistochemistry was used to evaluate vascular density by CD31 (red) and apoptosis by TUNEL (green). Although minimal numbers of TUNEL þ cells were detected in vehicletreated tumors, in sunitinib-treated animals, we observed extensive apoptosis of tumor cells (green) as well as apoptosis of tumor-associated endothelial cells (yellow) (Figure 7e ). Vessel density was determined by staining with antibodies against CD31. Vascular density was significantly reduced in sunitinib-treated tumors (P ¼ 0.009; Figure 7f ).
Discussion
Clinical outcomes are poor for children with refractory neuroblastoma and new therapeutic strategies are needed. Several RTK signaling pathways, including VEGFRs, EGFR, PDGFR and c-KIT, have been validated as therapeutic targets for solid tumors. In this study, we have investigated the expression and potential role of RTKs in neuroblastoma, and the potential mechanisms by which multikinase inhibitors exert their biological effects. First, we found that neuroblastoma tumor cells were heterogeneous in that they expressed multiple targetable RTKs. Second, we report differential regulation of HIF-1a and HIF-2a by RTK activation. Specifically, ligand-induced activation of multiple redundant RTKs, including RET, VEGFR-1, PDGFR-b and EGF, increased HIF-1a levels in normoxia, whereas only VEGFR-1 activation increased HIF-2a. Knockdown of any single RTK had minimal effects on cell viability, and did not alter HIF-1a levels. However, multikinase inhibition using TKIs such as sunitinib inhibited hypoxia-induced HIF-1a, HIF-2a and VEGF in addition to directly inducing cell-cycle arrest and apoptosis in neuroblastoma cells, suggesting that signaling through redundant RTK pathways directly affect cell proliferation, survival and angiogenesis in neuroblastoma. Consistent with this finding, in a xenograft model of neuroblastoma, sunitinib induced apoptosis of both tumor cells and tumorassociated endothelial cells and reduced HIF-1a levels. Collectively, these data indicate that these agents may be effective against neuroblastoma because of their dual activity against tumor cells and the tumor-associated vasculature, and may exert antiangiogenic effects through multiple mechanisms.
A recent preclinical study by Zhang et al. (2009) demonstrates that sunitinib is effective at inhibiting the in vivo growth and metastasis of neuroblastoma. Our data are in agreement with this report and extends these findings, providing a mechanism by which sunitinib decreases angiogenesis and invasiveness of tumor cells.
Activation of some RTKs, for example, EGFR in prostate, lung and breast cancer (Zhong et al., 2000; Phillips et al., 2005; Peng et al., 2006) , has been shown to increase HIF-1a levels in a hypoxia-independent, cell type-specific manner. Evidence for the role of RTK activation in regulating HIF-1a expression in neuroblastoma comes from a recent report that demonstrated the existence of a hypoxia-driven VEGF/VEGFR-1 autocrine loop modulating HIF-1a (Das et al., 2005) . We report that ligand-induced activation of RET, EGF and PDGFR-b in addition to VEGFR-1 increased HIF-1a levels in normoxia. To our knowledge, this is the first study demonstrating that HIF-1a levels are regulated by RET and PDGFR-b. Transcription of the RET ligand, GDNF, is thought to be hypoxiaregulated, possibly through HIF-1a (Yamagata et al., 2002) , and the expression of ligands for PDGFR-b, EGFR and VEGFR is HIF-1a controlled, suggesting the presence of a feed-forward loop (Semenza, 2003; Yoshida et al., 2006) . Indeed, the observation that multiple RTKs regulate HIF may represent a normal, It is noteworthy that VEGFR-1, but not other RTKs, induced rises in HIF-a In light of the finding that VEGFR-1 activation on pancreatic cancer cells mediates epithelial-mesenchymal transition , and our finding that HIF-2a overexpression promotes an epithelial-mesenchymal transition phenotype (Kim et al., 2009) , it suggests a role for the VEGFR-1/HIF-2a pathway in tumor cell invasiveness and mesenchymal phenotype.
The finding that multiple RTKs can regulate HIF-1a extends the earlier findings that multiple redundant RTKs are concomitantly activated and maintain downstream signaling in glioblastoma (Stommel et al., 2007) , potentially limiting the efficacy of therapies targeting a single pathway. In this study, multikinase inhibition with sunitinib and sorafenib, but not knockdown of the individual RTK targets of the drug, reduced HIF-1a levels in normoxia or hypoxia and led, in most cell lines, to cell-cycle arrest and induction of apoptosis. This finding has several implications for therapeutic approaches to neuroblastoma and other diseases.
First, it suggests that determining the specific profile of kinases active in a particular tumor may be important for selecting rational therapeutic combinations. Although there were similarities among the neuroblastoma cell lines, and all had evidence of more than one activated RTK, there were also clearly some RTKs present in only a minority of cell lines.
Second, it suggests that multitargeted approaches are likely to have greater antitumor activity than approaches targeting a single pathway provided the relevant targets can be blocked with acceptable toxicity. In this context, it is interesting to note that multitargeted kinases such as sunitinib, sorafenib and vandetanib have shown significant clinical activity as a single agent in a variety of solid tumor types including non-small cell lung cancer cell, RCC and hepatocellular carcinoma (Sandler et al., 2006; Kane et al., 2009; Pickering et al., 2009) , whereas for the VEGF monoclonal antibody bevacizumab, single-agent activity has mainly been limited to RCC (Yang, 2004) .
Third, our finding that multiple RTKs can regulate HIF-1a and VEGFR-1 regulates HIF-2a in both normoxia and hypoxia suggests a mechanism by which multikinase inhibitors may exert antiangiogenic effects in addition to directly inhibiting signaling in tumor endothelial cells. By reducing the hypoxia-and ligandinduced rises in HIF-1a and HIF-2a, as well as cell migration and HIF-regulated factors such as VEGF, it is conceivable that multikinase inhibitors may blunt compensatory pathways contributing to therapeutic resistance. As HIFs regulate numerous proangiogenic cytokines, this effect may be profound (Semenza, 2003) . This drug effect would not necessarily be detectable by standard cell growth or apoptosis assays in vitro, but may nevertheless contribute to in vivo activity. The potential contribution of RET signaling in the regulation of angiogenesis pathways may help explain our previous observation that the VEGFR/EGFR/RET inhibitor, ZD6474, inhibited in vivo growth and tumor angiogenesis of neuroblastoma xenografts, whereas the combination of bevacizumab and the EGFR TKI erlotinib did not (Beaudry et al., 2008) . ZD6474 is currently undergoing clinical testing in children with refractory neuroblastoma, which should help address whether these targets are clinically relevant.
VEGFR-1 was initially identified as a facilitator of monocyte migration, but has since been shown to promote migration of colorectal and pancreatic cancer cells (Wey et al., 2005; Lesslie et al., 2006) . VEGFR-1 is elevated in advanced-stage neuroblastoma (Fakhari et al., 2002) . We treated SK-N-AS cells with the VEGFR-1-specific ligand, VEGF-B, and observed increased migration. VEGF-B-induced migration was likely limited by the saturation of receptors with tumor cell-produced ligand. This notion was corroborated by ELISA analysis revealing high VEGF secretion. Sunitinib, but not sorafenib, reduced cell migration to below baseline values, suggesting a role for VEGFR-1 in the migration of neuroblastoma tumor cells, and indicating another mechanism by which sunitinib may inhibit the progression of this malignancy.
Sunitinib and sorafenib are known to have antiangiogenic activity by acting on VEGFR localized on the tumor vasculature. Our findings that TKIs such as sunitinib abrogate hypoxia-induced expression of HIF-1a and HIF-2a and decrease VEGF production in tumor cells indicate that TKIs may impair tumor angiogenesis by directly acting on endothelial cells and also by indirectly decreasing the secretion of proangiogenic molecules from the tumor cells. Finally, our study provides evidence that activation of multiple RTKs may redundantly contribute the regulation of the HIF pathway under normoxia and hypoxia.
Although it was not directly addressed here, this redundancy in signaling suggests that activation of other RTKs is one potential mechanism by which hypoxia-independent upregulation of HIFs, and therapeutic resistance to RTK inhibitors, may occur after prolonged treatment. It is worth noting that all RTKs were not identical as there were differences observed in the biological effects (for example, VEGFR-1-mediated upregulation of HIF-2a) mediated by certain RTKs. Taken together, these findings suggest that blockade of any single RTK in isolation is unlikely to be an effective therapeutic strategy in neuroblastoma and that the antiangiogenic effects of multikinase inibitors may result from effects on tumor signaling pathways as well as direct effects on tumor endothelium. 
Materials and methods
Mice and tumor cell lines
Expression of RTKs
Cells were washed in phosphate-buffered saline and lysed in protein lysis buffer (1% NP-40, 20 mmol/l Tris-HCl (pH 8), 137 mmol/l NaCl, 10% glycerol, 2 mmol/l EDTA and protease inhibitor cocktail tablets; Roche, Indianapolis, IN, USA). Protein (40 mg) was used for western blotting along with antibodies against RET, PDGFR-a and PDGFR-b (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blots were probed with antibodies against b-actin or vinculin (Sigma-Aldrich, St Louis, MO, USA) as a loading control.
VEGFR-1, -2 and -3, and c-Kit were evaluated by flow cytometry. Cells were labeled with phycoerythrin (PE)-conjugated VEGFR-1 (R&D Systems, Minneapolis, MN, USA), PerCP-Cy7-conjugated c-Kit (Beckman Coulter, Fullerton, CA, USA) and allophycocyanin-conjugated VEGFR-3 (R&D Systems) antibodies. Separately, cells were labeled with VEGFR-2-PE (R&D Systems). Cells stained with immunoglobulin G1 isotype controls labeled with PE, PerCp-Cy5, PerCP-Cy-7 and APC (BD Biosciences Pharmingen, San Jose, CA, USA) were used as negative controls. Staining was analyzed with an eight-color FACSCanto (BD Biosciences).
Cell viability assay
Neuroblastoma cells (2000 cells per well in 96-well plates) were treated with 10% FBS media with or without sunitinib, sorafenib or imatinib. After 5 days, MTT (Sigma-Aldrich) was added. After 2 h, media was removed, 100 ml of dimethyl sulfoxide was added and plates were read at a wavelength of 570 nm.
Cell-cycle analysis Neuroblastoma cells were treated with 1 mM sunitinib or sorafenib for 72 h in 10% FBS RPMI and stained with propidium iodide solution (50 mg/ml propidium iodide, 0.1% Triton X-100 in phosphate-buffered saline) for 15 min. Flow cytometry was performed on a FACSCalibur flow cytometer (BD Biosciences).
siRNA transfection
We transfected cells with siRNA targeting PDGFR-b, VEGFR-1, RET, HIF-1a, HIF-2a and control siRNA at a final concentration of 100 nM using DharmaFECT 2 (Dharmacon Inc., Lafayette, CO, USA). Medium was replaced after 24 h. Protein was isolated after 96 h. Separately, 48 h after transfection, SK-N-AS cells were plated in a 96-well plate (3000 cells per well). Viability was evaluated by MTT assay at 24 h (to control for differences in plating efficiency) and at 5 days.
HIF expression SK-N-AS cells were serum starved for 24 h and stimulated with 50 ng/ml GDNF (Pepro Tech Inc., Rocket Hill, NJ, USA), PDGF-BB, VEGF-B or EGF (R&D Systems). Protein was collected after 3, 15 and 48 h. SK-N-AS cells were incubated in normoxia or hypoxia (0.1% O 2 ) with or without 1 mM sunitinib, sorafenib or imatinib for 18 h, and protein lysates were collected. HIF-1a and HIF-2-a antibodies used in western blots were obtained from Novus Biologicals (Littleton, CO, USA). HIF-1a ELISA (R&D Systems) was performed according to the manufacturer's instructions. For HIF stability experiments, SK-N-AS cells were serum starved and incubated in 0.1% O 2 for 3 h. Cycoheximide was added (100 ng/ml) alone or with 1 mM sunitinib. Cells were incubated in hypoxia for the times indicated. Separately, SK-N-AS cells were serum starved overnight and pretreated with or without 1 mM sunitinib, sorafenib or imatinib in 0.1% O 2 for 3 h. Proteosome inhibitor MG-132 (10 mM) was added, and cells continued incubation in 0.1% O 2 for 1 h.
VEGF ELISA VEGF secretion was evaluated by ELISA (R&D Systems). Cells were seeded into a six-well dish, and pretreated with 10% FBS RPMI with or without 1 mM sunitinib, sorafenib or imatinib for 3 h. Medium was replaced with 1 ml of 10% FBS media with or without 1 mM drug; cells were incubated in normoxia or 0.1% O 2 for 12 h.
Reverse transcriptase PCR Total RNA was extracted using Trizol (Life Technologies, Carlsbad, CA, USA), and purified with the RNeasy kit (QIAGEN, Hilden, Germany). We used SuperScriptTM III RNase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) to convert RNA into cDNA. Oligonucleotide primers were obtained from Dharmacon Inc. Data was normalized to GAPDH mRNA levels.
Migration assay
In total, 700 ml of serum-free RPMI containing VEGF-B (50 ng/ml), sunitinib (1 mM) and sorafenib (1 mM) was added to the lower compartment of 24-well transwell migration inserts (8.0 mm pore size; Fisher Scientific, Pittsburgh, PA, USA). SK-N-AS cells (5 Â 10 4 ) were added to the upper chambers and incubated for 20 h. Cells in the upper compartment were removed. Cells that migrated to the underside of the membrane were stained and counted under low magnification ( Â 40).
Xenograft studies
We injected 7 Â 10 6 SK-N-SH cells subcutaneously into NOD/ SCID/IL2R-g mice. Once tumors were palpable (B5 mm in diameter), mice were treated daily with vehicle (1% or 40 mg/kg sunitinib by oral gavage (five animals per group). On day 39 of treatment, animals were euthanized; tumors were excised and weighed. For tumors designated for HIF-1a and immunohistochemical analysis, animals were treated daily with vehicle or 40 mg/kg sunitinib for 5 days. Tumors were embedded in OCT, Inc., Elkhart, IN, USA) and frozen in liquid nitrogen.
Immunohistochemistry
Frozen tumor sections were fixed in acetone, acetone/chloroform and acetone, washed and incubated in blocking solution (5% normal horse serum and 1% normal goat serum). To visualize endothelial cells, we used monoclonal anti-mouse CD31 antibody (1:400, Pharmingen) and Alexa 594 conjugated secondary antibody (Molecular Probes, Eugene, OR, USA). Analysis of apoptotic cells was performed using a commercially available TUNEL kit (Promega, Madison, WI, USA) as described (Bruns et al., 2000) . Microvascular density was determined using immunofluorescence microscopy; we quantified the number of structures positive for CD31 in five random 0.159-mm 2 fields at a magnification of Â 100 using Scion software (Scion Corporation, Frederick, MD, USA).
Statistical analysis
Statistical analysis of results was performed using Student's t-test (two tailed). A P value p0.05 was considered statistically significant.
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